Our pipeline is composed of IP protected, first-in-class potential assets of novel medicines for significant unmet need, developed via in-house R&D and partnerships through in-license and collaboration with global pharmaceutical and biotech companies. We focus on neurodegenerative and neurological injury disorders by enhancing neuroprotection/repair and controlling neuroinflammation.

Asset Indication Discovery Preclinical IND Phase I Phase II
4B06-01 ALS (IIT)
4B71-01 ALS
4B01-03 Glaucoma
4B03-04 Chronic pain
4B02-01 ALS
4B05-07 Stroke
4B07-05 AD
4B08-05 AD
4B10-08 AD